François Bertucci
François Bertucci is an expert in Oncology at Institut Paoli-Calmettes (France). As of October 2026, ScienceLeadR ranks François Bertucci in the top 1% of experts worldwide for Sarcoma, Breast Diseases and Breast Neoplasms. François Bertucci has authored 780 publications, the most recent in 2026, and is an investigator in 41 clinical trials, 10 of them ongoing. SLR score: 2,761 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Biochemistry - Gynecology - Dermatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1999 - 2026
Number : 780
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Head & Neck and Shoulder Desmoid-Type Fibromatosis: Presentation and Natural History of These Ultra-Rare Locations. PMID 42905937 — fibromatosis, aggressive, natural history, pain, neoplasms, history | Cancer Med | 2026 | 0 |
| Multiscale modeling uncovers macrophage infiltration and TNF-α signaling networks for targeting in inflammatory breast cancer tumor emboli. PMID 42607569 — cells, genes, breast neoplasms, immunophenotyping, macrophages, neoplasms, inflammatory breast neoplasms, breast, therapeutics, intravital microscopy | Breast | 2026 | 0 |
| Deni Study: Real-World Data on the Use of Nirogacestat in Patients With Desmoid Tumors in the French Sarcoma Group. PMID 42522292 — fibromatosis, aggressive, pain, neoplasms, sarcoma, fatigue, drug tapering, therapeutics | Int J Cancer | 2026 | 0 |
| TERT drives liver tumorigenesis beyond telomere elongation. PMID 42392980 — cells, genes, catenins, biological science disciplines, neoplasms, telomerase, liver, carcinogenesis, telomere, mutation, gene expression | Life Sci Alliance | 2026 | 0 |
| Tumor cell-derived extracellular vesicles foster the immunosuppressive landscape of pancreatic cancer. PMID 42390925 — cells, extracellular vesicles, pancreatic neoplasms, monocytes, macrophages, neoplasms | J Clin Invest | 2026 | 1 |
Clinical Studies 41
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
10 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| INTER EWING 1 International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma Trial 1 2024-511989-36-00 — radiotherapy, sarcoma, ewing, biomedical research, drug therapy, sarcoma, research, chemotherapy | Phase 3 | Recruiting | 2025 |
| Interest of post operative chemotherapy in patients with localized uterine leiomyosarcoma suspected to have a high risk of relapse based on a biologic test performed on the tumor 2023-506350-21-00 — leiomyosarcoma, neoplasms, classification, drug therapy, chemotherapy, adjuvant, chemotherapy | Phase 2 | Recruiting | 2025 |
| Testing Two Different Drugs (Sacituzumab govitecan and Trastuzumab deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple negative Breast Cancer NCT07151586 — research design, triple negative breast neoplasms, breast neoplasms, pharmaceutical preparations, neoplasms, disease progression, neoplasm metastasis, breast, response evaluation criteria in solid tumors, therapeutics, trastuzumab | Phase 2 | Not yet recruiting | 2026 |
| Interest of Post operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour NCT06524583 — leiomyosarcoma, uterus, doxorubicin, drug therapy, chemotherapy, adjuvant, trabectedin, chemotherapy | Phase 2 | Recruiting | 2025 |
| Trans RosaLEE Study a Biomarker directed Translational Study NCT05529862 — cells, genes, blood, breast neoplasms, neoplasms, biopsy, biomarkers, hormones, breast, therapeutics, edetic acid | N/A | Active not recruiting | 2023 |
LeadR Networks
Main global connection map